Drugs / LY3848575
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05727072 | Feb 2023 → Feb 2024 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06568042 | Aug 2024 → Jan 2026 | neuropathy, painful, sensory peripheral neuropathy | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3848575 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05727072 ↗ |
| Route | Intravenous | “Administered IV.” NCT05727072 ↗ |